This conference poster presents data on the pregnancy rates and outcomes amongst women on combination antiretroviral therapy (ART) in the Ugandan/Zimbabwean DART trial. 1867 of the 2156 women enrolled in the trial were of child-bearing age; none were pregnant at enrolment. Pregnancy rates in this populationof HIV-infected African women increased after the 1st year on ART and declined from the 4th year on ART. Rates of pregnancy were higher among the younger age group and among women with less-severe HIV clinical disease. High rates of foetal loss were observed and are constant over time. This may be due to improved reporting in the clinical study; however, increased foetal loss in HIV-infected women has been reported in other studies. Rates of congenital abnormalities in this study are low and similar to those previously reported. Few women in DART shose to breastfeed. No baby from this cohort is known to be HIV-infected. Continued documentation and outcome event monitoring from similar treatment cohorts is necessary. This will contribute to the knowledge base on the effects of antiretroviral therapy on pregnancy, the neonatal period, early infancy and childhood.
Munderi, P.; Wilkes, H.; Tumukunde, D.; Chidziva, E.; Nalumenya, R.; Gilks, C.F.; Zalwango, E.; Spyer, M.; Kyomugisha, H.; Lutwama, F.; Kikaire, B.; Kityo, C.; Reid, A.; Gibb, D.M. Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy (ART) in the DART trial. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. (2009) 1 pp.
Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy (ART) in the DART trial.